Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial
Last Updated: Thursday, July 22, 2021
The incidence of epidermal growth factor receptor inhibitor (EGFRI)-induced papulopustular rash ranges from 60% to 85%. This study found that prophylactic topical chloramphenicol 3% + prednisolone 0.5% (CHL-PRED) was more effective in treating EGFRI-induced rash than aqua cream.
Advertisement
News & Literature Highlights